RNAi for com­mon dis­eases? Al­ny­lam plans to forge a path for­ward, start­ing with new obe­si­ty gene tar­get

Just over a month af­ter it scored an ap­proval for a next-gen RNAi ther­a­py for hAT­TR amy­loi­do­sis, Al­ny­lam has un­veiled a bit more on where it plans to go next.

The Cam­bridge, MA-based bio­phar­ma an­nounced Wednes­day morn­ing that it would be putting its RNAi tech­nol­o­gy to­ward some much, much broad­er in­di­ca­tions — car­diometa­bol­ic dis­eases, which im­pli­cates a broad range of con­di­tions, such as heart dis­ease, di­a­betes and stroke, that col­lec­tive­ly are the lead­ing cause of death in the world.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.